Navocaftor is under clinical development by Sionna Therapeutics and currently in Phase II for Cystic Fibrosis.
Vertex has won two cystic fibrosis approvals from the FDA, but the agency included high-level safety warnings.
As Vertex Pharmaceuticals reels from a painful trial readout for its pain candidate suzetrigine, the Boston biotech has ...
Whether you are dealing with severe consequences of cystic fibrosis or want to get ahead the symptoms, these tips will help.
Allison Angell, the first person in the UK to have all of her major organs transplanted, has died aged 46—more than a decade ...
The new combination, dubbed Alyftrek, is designed to improve on the Trikafta, a product that generated sales of $8.9 billion ...
According to Vertex Pharmaceuticals, approximately 300 additional people with CF are now eligible to receive treatment.
Want to stay on top of the science and politics driving biotech today? Sign up to get our biotech newsletter in your inbox.
A $42,000 grant from NASA and INBRE will further CF research, through a collaborative effort spanning to India and the United Kingdom.
The Boomer and Gunnar Esiason Story," detailing a remarkable father-son journey of perseverance and resilience.
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback